Sanuwave Health (NASDAQ:SNWV) Shares Up 0.6% – Still a Buy?

Sanuwave Health Inc. (NASDAQ:SNWV)’s stock price rose 0.6% during trading on Friday . The stock traded as high as $22.62 and last traded at $21.51. Approximately 67,141 shares changed hands during mid-day trading, an increase of 27% from the average daily volume of 52,773 shares. The stock had previously closed at $21.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Sanuwave Health in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Sanuwave Health currently has an average rating of “Moderate Buy” and an average price target of $54.00.

Sanuwave Health Stock Up 0.6%

The business’s 50 day moving average price is $25.79 and its 200-day moving average price is $30.81. The company has a market cap of $184.56 million, a PE ratio of -16.55 and a beta of 1.32.

Hedge Funds Weigh In On Sanuwave Health

A number of institutional investors have recently added to or reduced their stakes in SNWV. Legal & General Group Plc purchased a new position in Sanuwave Health in the 2nd quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Sanuwave Health during the second quarter worth about $46,000. Farther Finance Advisors LLC acquired a new position in shares of Sanuwave Health in the third quarter worth about $57,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Sanuwave Health in the second quarter worth about $52,000. Finally, Russell Investments Group Ltd. purchased a new position in Sanuwave Health in the third quarter valued at about $67,000. Institutional investors and hedge funds own 42.53% of the company’s stock.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.